Calidi Biotherapeutics
CLDI | AMEX
$0.59
-$0.03 (-5.13%)
At close: Nov 16, 2026, 3:59 PM ET
$0.58
-$0.01 (-0.85%)
After-hours:
Nov 16, 2026, 5:13 PM ET
Calidi Biotherapeutics Company Profile
Company profile explainedCompany Profile
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Eric E. Poma | Chief Executive Officer & Director |
| Andrew C. Jackson | Chief Financial Officer & Corporate Secretary |
| Antonio Fernandez Santidrian | Head of Technical Operations & Chief Scientific Officer |
| Guy Travis Clifton | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 25, 2026 | 8-K | Current Report |
| Sep 22, 2026 | 8-K | Current Report |
| Sep 17, 2026 | 424B5 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
Calidi Biotherapeutics
| Country | United States |
| IPO Date | Nov 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Eric E. Poma |
Contact Details
4475 Executive Drive San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | CLDI |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001855485 |
| CUSIP Number | 320703507 |
| ISIN Number | US3207035078 |
| SIC Code | 6770 |
Add to Watchlist
Select watchlists to add or remove CLDI